Evidence map›Paper›PMID 40175772›Full record

SynthesisOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2025

Association of β-adrenergic receptor blockers use with the risk of fracture in adults: a systematic review and meta-analysis.

Lanxiao Liu, Yajie Wang, Baizhou Tan, Peng Huang

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lanxiao Liu *Center for Evidence-Based Medicine, School of Public Health, Jiangxi Medical College, Nanchang University, No. 461, Bayi Avenue, Donghu District, Nanchang, 330006, China.
Yajie Wang *Center for Evidence-Based Medicine, School of Public Health, Jiangxi Medical College, Nanchang University, No. 461, Bayi Avenue, Donghu District, Nanchang, 330006, China.
Baizhou Tan *Center for Evidence-Based Medicine, School of Public Health, Jiangxi Medical College, Nanchang University, No. 461, Bayi Avenue, Donghu District, Nanchang, 330006, China.
Peng HuangCenter for Evidence-Based Medicine, School of Public Health, Jiangxi Medical College, Nanchang University, No. 461, Bayi Avenue, Donghu District, Nanchang, 330006, China. huangpengncu@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStudies have shown that beta-antagonists, an antihypertensive drug, may be associated with fracture risk in adult users. However, this conclusion remains controversial. This meta-analysis was used to explore the association between beta-receptor antagonist use and fracture risk in adult patients.

methodsWe searched Embase, Medline, PubMed, and Web of Science; finally, 16 articles were identified, and the extracted odds ratio (OR), hazard ratio (HR), and 95% confidence interval (95% CI) were used to estimate the association between beta-blockers and the risk of fracture in adult patients. All the results are adjusted. Sensitivity analysis and Egger's test were employed to assess the stability of the results and potential publication bias.

resultsWe included eight cohort studies, one of which was only used for subgroup analysis because it only discussed the male and female groups separately and did not discuss the combined population. Thus, we included seven studies in which cohort studies did not find an association between beta-receptor antagonists and fracture risk, the HR is 0.96 (95% CI: 0.88-1.05; P = 0.41). Nine case-control studies included 156,437 beta-blockers users and 432,288 non-users for analysis showed that beta-receptor antagonists would reduce the risk of fracture in middle-aged and elderly users, the OR is 0.86 (95% CI: 0.77-0.95; P < 0.0001). In the subgroup analysis by the sites of fracture, no association was found between beta-receptor antagonists and fracture risk. However, in analyzing groups stratified by gender, beta-receptor antagonists reduce the fracture risk.

conclusionIn cohort studies, no association was found between beta-receptor antagonists and fracture risk. However, beta-receptor antagonists have been shown to reduce the risk of fractures in adult users in case-control studies. The results of this study need careful interpretation for the reason that case-control studies are inferior to cohort studies in determining cause and effect and the lack of enough randomized controlled trials (RCTs).

Indexed as

Adrenergic beta-AntagonistsAntihypertensive AgentsOsteoporotic FracturesAdultFemaleHumansMaleRisk AssessmentAdrenergic beta-AntagonistsAntihypertensive AgentsFracture RiskMeta-analysisβ-Adrenergic Receptor Blocker

Identifiers

PMID40175772

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.